Bret  Christensen net worth and biography

Bret Christensen Biography and Net Worth

EVP of Insulet
Mr. Christensen has served as our Executive Vice President and Chief Commercial Officer since February 2019. Prior, he served as our Senior Vice President and Chief Commercial Officer since May 2017. He brings more than 20 years of commercial experience to Insulet. Mr. Christensen joins the Company from Myriad Genetics, where he served as General Manager of Preventive Care, the company's largest business unit, leading a team of more than 350 employees across all commercial functions. Prior to Myriad Genetics, Mr. Christensen held a series of executive positions at Hologic Corporation, including Vice President of Sales and Marketing of its Gynecologic Surgical Products division. Prior to Hologic, he led key market development and sales teams at Cytyc Corporation. Mr. Christensen earned a B.S. in Business Management from Utah Valley University and received an MBA from the University of Utah.

What is Bret Christensen's net worth?

The estimated net worth of Bret Christensen is at least $3.31 million as of August 24th, 2022. Mr. Christensen owns 19,551 shares of Insulet stock worth more than $3,307,638 as of March 28th. This net worth estimate does not reflect any other assets that Mr. Christensen may own. Learn More about Bret Christensen's net worth.

How do I contact Bret Christensen?

The corporate mailing address for Mr. Christensen and other Insulet executives is 100 NAGOG PARK, ACTON MA, 01720. Insulet can also be reached via phone at (978) 600-7000 and via email at [email protected]. Learn More on Bret Christensen's contact information.

Has Bret Christensen been buying or selling shares of Insulet?

Bret Christensen has not been actively trading shares of Insulet during the past quarter. Most recently, Bret Christensen sold 2,900 shares of the business's stock in a transaction on Wednesday, August 24th. The shares were sold at an average price of $264.24, for a transaction totalling $766,296.00. Following the completion of the sale, the executive vice president now directly owns 19,551 shares of the company's stock, valued at $5,166,156.24. Learn More on Bret Christensen's trading history.

Who are Insulet's active insiders?

Insulet's insider roster includes Charles Alpuche (COO), Eric Benjamin (SVP), Luciana Borio (Director), Bret Christensen (EVP), Sally Crawford (Director), John Fallon (Director), James Hollingshead (CEO), Dan Manea (SVP), Wayde McMillan (CFO), Shacey Petrovic (CEO), Prem Singh (SVP), and Michael Spears (SVP). Learn More on Insulet's active insiders.

Are insiders buying or selling shares of Insulet?

In the last twelve months, Insulet insiders bought shares 2 times. They purchased a total of 5,551 shares worth more than $1,006,994.42. In the last twelve months, insiders at the medical instruments supplier sold shares 7 times. They sold a total of 49,927 shares worth more than $10,235,978.05. The most recent insider tranaction occured on February, 28th when Director Shacey Petrovic sold 11,609 shares worth more than $1,891,338.28. Insiders at Insulet own 0.9% of the company. Learn More about insider trades at Insulet.

Information on this page was last updated on 2/28/2024.

Bret Christensen Insider Trading History at Insulet

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/24/2022Sell2,900$264.24$766,296.0019,551View SEC Filing Icon  
8/26/2021Sell3,000$294.13$882,390.0016,331View SEC Filing Icon  
8/12/2020Sell5,000$201.54$1,007,700.00View SEC Filing Icon  
See Full Table

Bret Christensen Buying and Selling Activity at Insulet

This chart shows Bret Christensen's buying and selling at Insulet by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Insulet Company Overview

Insulet logo
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Read More

Today's Range

Now: $169.18
Low: $162.47
High: $169.25

50 Day Range

MA: $183.46
Low: $163.60
High: $206.03

2 Week Range

Now: $169.18
Low: $125.82
High: $335.91

Volume

996,101 shs

Average Volume

902,690 shs

Market Capitalization

$11.83 billion

P/E Ratio

58.14

Dividend Yield

N/A

Beta

0.98